Rockwell Medical, Inc.

RMTI

US7743743004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			5-day change	1st Jan Change
2.025 ^USD	-2.64%		+4.92%	+7.14%

05-30	Rockwell Medical, Inc. Promotes Tim Chole to Chief Commercial Officer	CI
05-14	Transcript : Rockwell Medical, Inc., Q1 2024 Earnings Call, May 14, 2024

ROCKWELL MEDICAL, INC. : Other Events (form 8-K)

January 15, 2020 at 06:19 am

Item 8.01 Other Events.

On January 14, 2020, Rockwell Medical, Inc. (the "Company") issued a press release announcing that the Company has entered into license and supply agreements with a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. for the rights to commercialize Triferic (ferric pyrophosphate citrate) in India. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Latest news about Rockwell Medical, Inc.

Rockwell Medical, Inc. Promotes Tim Chole to Chief Commercial Officer	05-30	CI
Transcript : Rockwell Medical, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
Rockwell Medical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Earnings Flash (RMTI) ROCKWELL MEDICAL Reports Q1 Revenue $22.7M, vs. Street Est of $21.7M	05-14	MT
Rockwell Medical, Inc. Provides Earnings Guidance for the Year 2025	05-14	CI
Rockwell Medical, Inc. Revises Earnings Guidance for the Year 2024	05-14	CI
Rockwell Medical Continues to Expand Its Distribution Capabilities in Western United States	04-17	CI
Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda	04-04	CI
HC Wainwright Cuts Price Target on Rockwell Medical to $9 From $11, Keeps Buy Rating	03-25	MT
Transcript : Rockwell Medical, Inc., Q4 2023 Earnings Call, Mar 21, 2024	03-21
(RMTI) ROCKWELL MEDICAL Expects Fiscal Year 2024 Revenue Range $84M - $88M	03-21	MT
Earnings Flash (RMTI) ROCKWELL MEDICAL Posts Q4 Revenue $22.1M	03-21	MT
Rockwell Medical, Inc. Provides Earnings Guidance for the Year 2024	03-21	CI
Rockwell Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Earnings Flash (RMTI) ROCKWELL MEDICAL Reports Q4 EPS $0.02	03-21	MT
Rockwell Medical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21	CI
Rockwell Medical, Inc. Provides Earnings Guidance for Fourth Quarter and Full-Year 2023	01-08	CI
Rockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending Fund	01-08	CI
Transcript : Rockwell Medical, Inc., Q3 2023 Earnings Call, Nov 14, 2023	11-14
Earnings Flash (RMTI) ROCKWELL MEDICAL Reports Q3 Revenue $23.8M	11-14	MT
Rockwell Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Rockwell Medical, Inc. Provides Financial Guidance for the Year 2023	11-14	CI
Rockwell Medical, Inc. Appoints Jesse Neri as Senior Vice President, Finance	23-10-18	CI
Rockwell Medical, Inc. Appoints Joan Lau, Ph.D. to the Company's Board of Directors	23-10-17	CI
Maxim Initiates Coverage on Rockwell Medical with Buy Rating, $5 Price Target	23-10-05	MT

Chart Rockwell Medical, Inc.

Duration

Period

More charts

Company Profile

Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers around the world. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. It is the supplier of life-sustaining hemodialysis concentrates products to dialysis clinics. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patientâs bloodstream. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Rockwell Medical, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.025 USD

Average target price

7 USD

Spread / Average Target

+245.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCKWELL MEDICAL, INC.	+7.14%	61.39M
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.49%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.15%	247B
NOVARTIS AG	+14.27%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals